Single-agent and Combination Data Support Clinical Development Plan
"The presentations at AACR speak to the potential of our locally- and
systemically-administered TPTs to provide patients with new therapeutic
options that offer improvements over existing antibody drug conjugates
(ADCs), both in combination with existing checkpoint inhibitors and as
single agents," said Stephen Hurly, President and Chief Executive
Details of the poster presentations are as follows:
tumor cell killing in a combination study with the anti-PD-1, nivolumab
Date & Time:
Session Category: Immunology
Session Title: T-cell Immunity to Cancer: New Progress
Presenter: Dillon, R.L.
Abstract Number: 614
Location: Walter E. Washington
Summary: This study evaluated the ability of VB4-845-mediated cell killing to elicit ICD and the effect of VB4-845-mediated cell killing when combined with the checkpoint inhibitor nivolumab in PDX tumor-bearing NOG mice. VB4-845 showed growth suppression of the injected tumor; growth inhibition of the contralateral, non-injected tumor was more pronounced with the addition of nivolumab. These data suggest that VB4-845 mediates tumor cell killing via an ICD pathway, and that the resulting cross-priming effect can enhance the anti-tumoral activity of immune checkpoint inhibitors.
and C6.5 diabody armed with deBougnanin overcome drug resistance to ADCs
comprised of anti-microtubule agents
Date & Time: Sunday, April 2, 2017 from 1:00 - 5:00 p.m. ET
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technology
Presenter: Chooniedass, S.
Abstract Number: 79
Location: Walter E. Washington
Summary: This study explored the differentiating mechanism of action of deBouganin, a de-immunized form of the ribosome inactivating protein bouganin. Data showed that treatment with chemotherapeutic agents or antibody drug conjugates comprised of small molecule compounds can lead to a subpopulation of drug-resistant tumor cells with cross-resistance to both similar agents, as well as to unrelated compounds, potentially leading to future treatment failures. In contrast, antibodies and antibody fragments armed with deBouganin can overcome these mechanisms of resistance and may therefore represent a more effective treatment option.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans
and prospects for the Company, the Company's strategy, future
operations, and other statements containing the words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation and conduct of pre-clinical studies and clinical trials, our
ability to successfully develop our product candidates and complete our
planned clinical programs, our ability to obtain marketing approvals for
our product candidates, expectations regarding our ongoing pre-clinical
studies and clinical trials, availability and timing of data from
pre-clinical studies and clinical trials, whether interim results from a
pre-clinical study or clinical trial will be predictive of the final
results of the study or trial or results of early pre-clinical and
clinical studies will be indicative of the results of future studies,
the adequacy of any clinical models, expectations regarding regulatory
approvals, and other factors discussed in the "Risk Factors" section of
the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and other reports filed with the
Stern Investor Relations
News Provided by Acquire Media